This vial holds 10 mg of Selank and 10 mg of Semax, two Russian heptapeptide nootropics that vendors sell together as a 1:1 blend.
A fixed-ratio blend requires component-aware arithmetic. Vial composition is kept separate from target amounts so component strengths are never presented as dose suggestions.
Choose the exact vial variant. The Advanced Blend workspace prefills each component and calculates every component concentration from one shared prepared volume.
Each listed number identifies how much of one component is present in the full vial. It does not establish how much of the blend to draw or how often.
Reported protocols describe how sources reconstitute and draw this vial as a whole, each tied to where it was said.
Each peptide's own page reports what studies and guides describe for it alone; the leading rows are repeated below.
The ratio is fixed by the vial, so a draw sized for one component sets the amount of all the others at the same time.
Selank / Semax Blend is 2 peptides in one vial. Each profile below is PubChem's record for that peptide, read from its own library page; the vial amount is what the label states for this blend, not an amount per draw.
Selank10 mg per vial
Semax10 mg per vial
What published studies and recent community write-ups report about amounts, timing and course length. 4 community-reported rows, each linked to its source. These are descriptions of what others report, not instructions, and nothing here is medical advice.
| Context | Dose | Frequency | Route | Course | Source |
|---|---|---|---|---|---|
| Community-reported4 rows | |||||
| Community nasal-spray convention for the 20 mg vial | About 100 mcg of each peptide per 50 microlitre spray, from 20 mg made up in 10 mL (2 mg/mL combined); 1 spray per nostril to start (200 mcg of each per day), then 1-2 sprays per nostril 1-2 times daily (300-600 mcg of each per day) | 1-3 times daily, morning first; at least 4 hours between doses on the heavier 2-3 sprays per nostril schedule | Intranasal spray from a pharmacy-grade bottle, primed with 2-3 actuations, with 30-60 seconds between sprays in the same nostril | 2-6 weeks activeCycle off when the acute need passes; some use the blend only on high-demand days | Community resource2026 |
| This 2026 profile is explicit that no published study has given Semax and Selank together (a 2020 fMRI study tested them as separate arms in the same volunteers) and that the blend's per-component figures are a community convention sitting below both drugs' Russian labels and below each drug's own community dose. It describes concentration variants (20 mg in 5 mL for about 200 mcg of each per spray, in 20 mL for about 50 mcg) and says anyone wanting a ratio other than 1:1 should buy the peptides separately. It gives 30 days refrigerated for the spray bottle while admitting that no stability document supports the figure. | |||||
| Community protocol page: subcutaneous or intranasal from a blended vial | 200-500 mcg of total blend per administration; 200 mcg to start, raised 100 mcg at a time | 1-2 times daily at the same times each day | Subcutaneous (abdomen, thigh or upper arm, rotated) or intranasal | 4-8 weeksNot specified | Community resource2026 |
| This page models a 10 mg blended vial made up with 3 mL (about 3.33 mg/mL, 33 mcg per unit), so its 200, 300 and 500 mcg steps are about 6, 9 and 15 units. The 10 mg + 10 mg vial sold here holds twice that, so the same 3 mL gives about 6.67 mg/mL and the unit counts halve. Its doses are totals for the pair, so each administration carries half as much of each peptide; the page names a vendor and cites no clinical source for the combination. | |||||
| Community stack guide: two vials, with notes on pre-blended vials | Semax 600 mcg (18 units) plus Selank 400 mcg (12 units) once daily from separate 10 mg vials each made up with 3 mL (3,333 mcg/mL); for a pre-blended 10 mg vial at the same dilution, a 0.18 mL draw is about 600 mcg of total blend | Once daily in the morning, with every Semax dose before 2 PM; many follow 5 days on and 2 off | Subcutaneous at separate sites with separate syringes, which the guide calls the off-label research route; intranasal is the original Russian-approved route | 4 weeks on (standard), 10-14 days (intensive) or 8 weeks at 5 days a week (extended)4 weeks off after the standard and extended cycles; 10-14 days off after the intensive one | Community resource2026 |
| This August 2026 guide treats two separate vials as standard and says a few suppliers sell pre-blended vials or nasal solutions; for those it says to check the actual milligram split on the label and accept that the ratio is locked, since Semax cannot be titrated independently of Selank. It describes running Selank alone for 5-7 days before adding Semax, titrating each independently over weeks 3-8 (Selank to 400-500 mcg and Semax to 500-800 mcg a day), and states that no clinical trial has tested the combined stack. Its intranasal figures for the Russian products are 2-3 drops per nostril, about 200-300 mcg per administration. | |||||
| Vendor dosage guide: the Russian nootropic stack line | Selank 250-500 mcg plus Semax 200-600 mcg per administration | 2-3 times daily | Intranasal | The same page's Selank cycles run 14 days (Russian pharmaceutical), 3-4 weeks (standard) or 6-8 weeks (extended)14 days, 1-2 weeks or 2-3 weeks off, matching the three cycle lengths | Community resource2026 |
| A European vendor's Selank guide, compiled from a third-party wiki, lists the pairing as a stack of two separately dosed peptides rather than a blended vial, so these amounts cannot be drawn from a 1:1 vial at the ratio stated. It is a vendor claim, and it describes diminishing returns above about 500 mcg of intranasal Selank and a 3 mL reconstitution transferred to a metered spray bottle of about 0.1 mL per spray for nasal use. | |||||
Community reports place effects within 15-30 minutes of a spray, Semax's focus first and Selank's calming effect building over 30-60 minutes, with a single dose lasting 4-8 hours. The profile notes that no trial or label establishes this timeframe.
Cumulative effects are described as building over the first one to two weeks of a cycle, which guides attribute to BDNF upregulation and stress adaptation seen in the component literature; nothing has measured this for the combination.
The common rhythms are 4 weeks on and 4 off, a 10-14 day intensive course with a matching break, or 5 days on and 2 off for up to 8 weeks; the Russian intranasal products run 14-21 day courses. The guide says neither peptide built tolerance or dependence in published trials, so cycling is framed as avoiding adaptation rather than managing withdrawal.
Plus 7 community resources (dosing guides, forum threads and vendor write-ups), reported above but not linked.
What sources report for each peptide on its own. In Selank / Semax Blend the vial ratio fixes the proportions, so one draw delivers every component at once and none can be raised without the others. The first rows from each component's table are shown here; its page carries the rest, each linked to its source. Descriptions of what others report, not instructions.
These fields come from the existing picker, blend catalog and observed presentation data. They are identity and availability context, not evidence of effectiveness.
This vial holds 10 mg of Selank and 10 mg of Semax, two Russian heptapeptide nootropics that vendors sell together as a 1:1 blend. Both peptides are registered in Russia only as nasal drops and are usually dosed intranasally; the vendor sells this pairing as a 20 mg lyophilised vial whose page disclaims nasal and injection use, and community guides either make the powder up as a nasal spray or inject it subcutaneously. No controlled study has tested the two co-formulated or given together, so the clinical record is on the component pages, and the blend-specific community doses sit below either drug's Russian label.
Fixed-ratio blend reference
Kept separate from single-peptide evidence and terminology.
Structured review queued
No evidence level is assigned until references and study models are reviewed.
Advanced Blend workspace
Calculator access performs arithmetic; it does not establish an amount or protocol.
No reviewed observation on file
The vial label remains the authoritative source for any calculation.
Each number is the vial amount for that component. It is not a per-draw amount.
2 curated references, each with its journal, year and study model, plus 7 community resources reported but not linked.